Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 mai 2024 02h00 HE | Source: Anaveon

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
23 mars 2023 03h00 HE | Source: Anaveon

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting

BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...
02 févr. 2023 02h00 HE | Source: Anaveon

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...